Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30157118 | 0.98 | ESR1 (0.38) | ESR1ESR2TLR8CYP1A2HSD17B1 | |
| SCHEMBL29977301 | 0.82 | GRM5 (0.45) | CYP1A2GRM5CACNA2D1CACNB2CACNA1C | |
| SCHEMBL26259230 | 0.82 | GRM5 (0.45) | CYP1A2GRM5CACNA2D1CACNB2CACNA1C | |
| SCHEMBL31491217 | 0.82 | PLAU (0.44) | CYP1A2GRM5LMNAPOLB | |
| SCHEMBL30259973 | 0.82 | CYP1A2 (0.35) | CYP1A2GRM5 | |
| SCHEMBL27814779 | 0.81 | ALDH1A1 (0.33) | CYP1A2GRM5CACNA2D1CACNB2CACNA1C | |
| SCHEMBL497591 | 0.80 | GRM5 (0.33) | CYP1A2GRM5CACNA2D1CACNB2CACNA1C | |
| SCHEMBL28433044 | 0.80 | GRM5 (0.33) | CYP1A2GRM5CACNA2D1CACNB2CACNA1C | |
| SCHEMBL29876075 | 0.79 | NQO2 (0.34) | ESR1ESR2MCL1NQO2CACNA2D1 | |
| SCHEMBL23043709 | 0.79 | NQO2 (0.34) | ESR1ESR2MCL1NQO2CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101924-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2025236100-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2025-11-20 | — | — | WO | disclosed |
| WO-2025217319-A1 | RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025151594-A1 | FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| CN-119790058-A | Fused cyclic KRAS inhibitors for the treatment of diseases | 荣山医药股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119677749-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2024243025-A1 | NAPHTHYL-SUBSTITUTED PYRIDO[4,3-D]PYRIMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Ikena Oncology, Inc. (US) | 2024-11-28 | — | — | WO | disclosed |
| EP-4442686-A1 | KRAS INHIBITORS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd (CN) | 2024-10-09 | — | — | EP | disclosed |
| CN-118679170-A | Nitrogen-containing heterocyclic compound, and preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024178304-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| WO-2023244713-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| CN-117203207-A | Bridged ring compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023173014-A1 | KRAS INHIBITORS AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023143312-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023098425-A1 | KRAS INHIBITORS, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023020347-A1 | PYRIMIDOPYRIDINE COMPOUND AND PREPARATION METHOD AND MEDICAL USE THEREFOR | 华润医药研究院（深圳）有限公司 | 2023-02-23 | — | — | WO | disclosed |
| WO-2023018809-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022228568-A1 | PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-11-03 | — | — | WO | disclosed |
| WO-2022232331-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| EP-4065583-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-10-05 | — | — | EP | disclosed |